corporate profile

Novocure (NASDAQ: NVCR) is a global oncology company striving to extend survival in some of the most aggressive forms of cancer through the development and commercialization of our innovative therapy, Tumor Treating Fields (TTFields). Our commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma (GBM), metastatic non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM). In the U.S., our therapy is approved by the U.S. Food and Drug Administration (FDA) under the Premarket Approval (PMA) pathway for use treating GBM and NSCLC, and under the Humanitarian Device Exemption (HDE) pathway for use treating MPM . We continue to explore the use of TTFields therapy for the treatment of GBM, NSCLC and pancreatic cancer.

corporate presentation clinical evidence
4
FDA-approved indications
30,000+
patients treated through January 2024
$509M
annual net revenues (2023)
$223M
annual R&D investments (2023)
4
ongoing phase 3 trials
view all

latest filings

date filing type filing download
October 30, 2024 8-K Current report filing
October 30, 2024 10-Q Quarterly Report
October 15, 2024 8-K Current report filing
October 09, 2024 3 Initial Statement of Beneficial Ownership
September 03, 2024 8-K Current report filing
August 06, 2024 4 Statement of Changes in Beneficial Ownership
August 06, 2024 4 Statement of Changes in Beneficial Ownership
August 06, 2024 4 Statement of Changes in Beneficial Ownership
August 06, 2024 4 Statement of Changes in Beneficial Ownership
August 06, 2024 4 Statement of Changes in Beneficial Ownership
August 06, 2024 4 Statement of Changes in Beneficial Ownership
August 05, 2024 4 Statement of Changes in Beneficial Ownership
July 25, 2024 S-8 POS Post-Effective Amendment to an S-8 filing
July 25, 2024 S-8 POS Post-Effective Amendment to an S-8 filing
July 25, 2024 S-8 POS Post-Effective Amendment to an S-8 filing
mission, vision and values

mission

Together with our patients, we strive to extend survival in some of the most aggressive forms of cancer by developing and commercializing our innovative therapy.

vision

Patient-forward: aspiring to make a difference in cancer

learn more

contact us

investorinfo@novocure.com
610-723-7427

sign up for email alerts

To receive notifications via email, enter your email address and select at least one subscription below. After submitting your information, you will receive an email. You must click the link in the email to activate your subscription. You can sign up for additional subscriptions at any time.

"*" indicates required fields

List
This field is for validation purposes and should be left unchanged.